<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04655794</url>
  </required_header>
  <id_info>
    <org_study_id>201800081B0</org_study_id>
    <nct_id>NCT04655794</nct_id>
  </id_info>
  <brief_title>Clinical Analysis of Safety in Latent Tuberculosis Infection Prophylaxis Treatment</brief_title>
  <official_title>Clinical Analysis of Safety in Latent Tuberculosis Infection Prophylaxis Treatment</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Chang Gung Memorial Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Chang Gung Memorial Hospital</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The treatment of latent TB with 3HP is an important issue for the prevention of active TB.&#xD;
      However, significant proportion of subjects receiving 3HP had adverse reaction. The main&#xD;
      purpose of this observation study is to identify subjects who have higher risk to develop&#xD;
      adverse reaction. Clinical characteristics and biomarker will be used to predict adverse&#xD;
      reaction.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 19, 2018</start_date>
  <completion_date type="Anticipated">February 12, 2021</completion_date>
  <primary_completion_date type="Actual">November 20, 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>sTREM1 between &gt;= grade 2 adverse reaction (SAR group) and&lt; grade 2 adverse reaction (Non-SAR group)</measure>
    <time_frame>Change from Baseline sTREM1 at 2 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>sTREM1 between &gt;= grade 2 adverse reaction (SAR group) and&lt; grade 2 adverse reaction (Non-SAR group)</measure>
    <time_frame>Change from Baseline sTREM1 at SARs</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>sTREM2 between &gt;= grade 2 adverse reaction (SAR group) and&lt; grade 2 adverse reaction (Non-SAR group)</measure>
    <time_frame>Change from Baseline sTREM1 at 2 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>sTREM2 between &gt;= grade 2 adverse reaction (SAR group) and&lt; grade 2 adverse reaction (Non-SAR group)</measure>
    <time_frame>Change from Baseline sTREM1 at SARs</time_frame>
  </primary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">500</enrollment>
  <condition>Adverse Reaction to Drug</condition>
  <condition>3HP</condition>
  <arm_group>
    <arm_group_label>had &gt;= grade 2 adverse reactions</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>had &lt;2 frade 2 adverse reactions</arm_group_label>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>3HP</intervention_name>
    <description>all patients taking 3HP under directly observed preventive therapy (DOPT) program</description>
    <arm_group_label>had &lt;2 frade 2 adverse reactions</arm_group_label>
    <arm_group_label>had &gt;= grade 2 adverse reactions</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        The newly identified LTBI subjects who wanted to receive LTBI preventive therapy with 3HP&#xD;
        were eligible for enrolment.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  close contact with active TB patients&#xD;
&#xD;
          -  patients with autoimmune diseases preceding biological therapy&#xD;
&#xD;
          -  health-care workers&#xD;
&#xD;
          -  other clinical conditions, which increased the risk of LTBI. LTBI was confirmed by&#xD;
             QuantiFERON-TB Gold In-Tube test (QFT-GIT; Qiagen, Valencia, CA, USA) with a cut-off&#xD;
             value of 0.35 IU/ml.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  age less than 20 years&#xD;
&#xD;
          -  pregnant women&#xD;
&#xD;
          -  active TB or suspected active TB in the clinical evaluation&#xD;
&#xD;
          -  severe liver disease&#xD;
&#xD;
          -  ESRD&#xD;
&#xD;
          -  organ transplantation&#xD;
&#xD;
          -  close contact with a multidrug-resistant TB patient&#xD;
&#xD;
          -  obesity (BMI&gt;30 Kgw/m2) and other conditions inappropriate for participation in this&#xD;
             study as judged by the investigators.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>100 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Tsai-Yu Wang</last_name>
    <phone>+886975368076</phone>
    <email>wang5531@gmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Institutional Review Board Chang Gung Medical Foundation</name>
      <address>
        <city>Taipei</city>
        <zip>333</zip>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tsai-Yu Wang, MD</last_name>
      <phone>886975368076</phone>
      <email>wang5531@gmail.com</email>
    </contact>
  </location>
  <location_countries>
    <country>Taiwan</country>
  </location_countries>
  <verification_date>November 2020</verification_date>
  <study_first_submitted>November 24, 2020</study_first_submitted>
  <study_first_submitted_qc>December 4, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">December 7, 2020</study_first_posted>
  <last_update_submitted>December 4, 2020</last_update_submitted>
  <last_update_submitted_qc>December 4, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">December 7, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tuberculosis</mesh_term>
    <mesh_term>Latent Tuberculosis</mesh_term>
    <mesh_term>Drug-Related Side Effects and Adverse Reactions</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

